N/A
Completed N=10
Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Pre-diabetes · impaired fasting glucose · impaired glucose tolerance
Source: ClinicalTrials.gov NCT01488279 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcomePrimary: Insulin Sensitivity — 1835.4; 1846.0 ratio without units — p=.983
Summary
The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Sensitivity |
1835.4; 1846.0 | .983 |
| SECONDARY Change in Active GIP |
— | — |
| SECONDARY Change in Active GLP-1 |
— | — |
| SECONDARY Change in Glucose Response |
4.219; 4.228 | .997 |
| SECONDARY Change in Insulin Secretion (AIRg or Acute Insulinogenic Response to Glucose) |
519.6; 558.6 | .460 |
Eligibility Criteria
Inclusion Criteria
- Men and women
- impaired fasting glucose
- We will stratify for weight and age.
Exclusion Criteria
- Known Type 2 DM
- Severe disease preventing participation in study
- On chronic steroids for any reason
- Already taking DPP-4 inhibitor
Data sourced from ClinicalTrials.gov (NCT01488279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.